Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral antiviral drugs, with no approved products and no revenue. Atea's lead program is a fixed-dose combination of bemnifosbuvir and ruzasvir, taken once daily, for the treatment of chronic hepatitis C virus (HCV) infection. Two global Phase 3 trials are currently underway — C-BEYOND (US/Canada) and C-FORWARD (outside North America) — with topline results expected in 2026 and an NDA submission to the FDA targeted for March 2027. If approved, the regimen would compete directly with Gilead's Epclusa and AbbVie's Mavyret, the two dominant HCV treatments. Atea argues its regimen is differentiated by a cleaner drug-drug interaction profile, no food effect, and an 8-week treatment course without a protease inhibitor. Atea's secondary pipeline candidate is AT-587, a nucleotide analog for chronic hepatitis E virus (HEV) infection targeting immunocompromised patients, for whom no approved therapies exist; this program is earlier-stage with a Phase 1 study anticipated mid-2026. Atea does not yet have a commercial organization and may partner with third parties for commercialization. If the HCV regimen is approved, Atea would owe Merck tiered royalties on net sales and milestone payments tied to regulatory and sales targets. The company is funded by its cash balance and is managing spend ahead of Phase 3 readouts, which management views as the key catalyst for any future partnership or M&A discussions.